Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Accured Expenses: 2012-2024

Historic Change in Accured Expenses for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $63.6 million.

  • Amphastar Pharmaceuticals' Change in Accured Expenses rose 2.80% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.2 million, marking a year-over-year decrease of 30.77%. This contributed to the annual value of $63.6 million for FY2024, which is 380.19% up from last year.
  • Amphastar Pharmaceuticals' Change in Accured Expenses amounted to $63.6 million in FY2024, which was up 380.19% from $13.2 million recorded in FY2023.
  • Amphastar Pharmaceuticals' 5-year Change in Accured Expenses high stood at $63.6 million for FY2024, and its period low was -$736,000 during FY2022.
  • For the 3-year period, Amphastar Pharmaceuticals' Change in Accured Expenses averaged around $25.4 million, with its median value being $13.2 million (2023).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Change in Accured Expenses slumped by 120.25% in 2022, and later skyrocketed by 1,898.51% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $20.1 million in 2020, then tumbled by 81.91% to $3.6 million in 2021, then slumped by 120.25% to -$736,000 in 2022, then spiked by 1,898.51% to $13.2 million in 2023, then surged by 380.19% to $63.6 million in 2024.